OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
Showing 14 citing articles:
Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
Xixi Liu, Kenneth K.W. To, Qinsong Zeng, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Xixi Liu, Kenneth K.W. To, Qinsong Zeng, et al.
Advanced Science (2025)
Open Access | Times Cited: 1
Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4
J Zeng, Yuan Fang, Zixuan Zhang, et al.
Oncogene (2024) Vol. 43, Iss. 29, pp. 2244-2252
Open Access | Times Cited: 6
J Zeng, Yuan Fang, Zixuan Zhang, et al.
Oncogene (2024) Vol. 43, Iss. 29, pp. 2244-2252
Open Access | Times Cited: 6
Modulation of N-glycosylation in the PD-1: PD-L1 axis as a strategy to enhance cancer immunotherapies
Monika Granica, Gustaw Laskowski, Paweł Link-Lenczowski, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189274-189274
Open Access
Monika Granica, Gustaw Laskowski, Paweł Link-Lenczowski, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189274-189274
Open Access
Naringenin: a potential therapeutic agent for modulating angiogenesis and immune response in hepatocellular carcinoma
Wenmei Wu, Xiangyu Qiu, Xiaofan Ye, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101254-101254
Open Access
Wenmei Wu, Xiangyu Qiu, Xiaofan Ye, et al.
Journal of Pharmaceutical Analysis (2025), pp. 101254-101254
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
The World of Immunotherapy Needs More Than PD-1/PD-L1—Two of the New Kids on the Block: LAG-3 and TIGIT
João Martins Gama, Paulo Ricardo Teixeira, Rui Caetano Oliveira
Onco (2024) Vol. 4, Iss. 3, pp. 116-130
Open Access | Times Cited: 1
João Martins Gama, Paulo Ricardo Teixeira, Rui Caetano Oliveira
Onco (2024) Vol. 4, Iss. 3, pp. 116-130
Open Access | Times Cited: 1
Baicalin attenuates PD-1/PD-L1 axis-induced immunosuppression in piglets challenged with Glaesserella parasuis by inhibiting the PI3K/Akt/mTOR and RAS/MEK/ERK signalling pathways
Shulin Fu, Jingyang Li, Jiarui You, et al.
Veterinary Research (2024) Vol. 55, Iss. 1
Open Access | Times Cited: 1
Shulin Fu, Jingyang Li, Jiarui You, et al.
Veterinary Research (2024) Vol. 55, Iss. 1
Open Access | Times Cited: 1
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
Jyoti Malhotra, Amy Huang, Arya Amini, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3603-3603
Open Access | Times Cited: 1
Jyoti Malhotra, Amy Huang, Arya Amini, et al.
Cancers (2024) Vol. 16, Iss. 21, pp. 3603-3603
Open Access | Times Cited: 1
Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders
Corneliu Toader, Călin Petru Tătaru, Octavian Munteanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13614-13614
Open Access | Times Cited: 1
Corneliu Toader, Călin Petru Tătaru, Octavian Munteanu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13614-13614
Open Access | Times Cited: 1
Construction and preclinical evaluation of a 124I-labelled bispecific antibody targeting PD-L1 and PD-L2
Yuan Yao, Yanan Ren, Xingguo Hou, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 52, Iss. 1, pp. 36-47
Closed Access
Yuan Yao, Yanan Ren, Xingguo Hou, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 52, Iss. 1, pp. 36-47
Closed Access
Monoclonal Antibody Therapies in Cancer Immunotherapy
Charuwan Thanawiroon, Bancha Yingngam
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 419-472
Closed Access
Charuwan Thanawiroon, Bancha Yingngam
Advances in medical diagnosis, treatment, and care (AMDTC) book series (2024), pp. 419-472
Closed Access
Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface
Sakuntala Gayen, Swarupananda Mukherjee, Sandipan Dasgupta, et al.
APOPTOSIS (2024)
Closed Access
Sakuntala Gayen, Swarupananda Mukherjee, Sandipan Dasgupta, et al.
APOPTOSIS (2024)
Closed Access
Evolving Treatment Landscape for Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma
Margaret C. Wheless, M.B. Comer, Michael K. Gibson
Current Oncology Reports (2024) Vol. 26, Iss. 11, pp. 1469-1488
Open Access
Margaret C. Wheless, M.B. Comer, Michael K. Gibson
Current Oncology Reports (2024) Vol. 26, Iss. 11, pp. 1469-1488
Open Access
Revolutionizing cancer treatment: Exploring novel immunotherapeutics, checkpoints, bispecifics, and vaccines in development
Anas Islam, Vijay Singh, Pooja S. Murkute, et al.
Advances in immunology (2024)
Closed Access
Anas Islam, Vijay Singh, Pooja S. Murkute, et al.
Advances in immunology (2024)
Closed Access
